Want to see STVN full AI Analyst Report?
STVN Stock Chart & Stats
$15.53
-$0.46(-1.91%)
At close: 4:00 PM EST
$15.53
-$0.46(-1.91%)
Day’s Range― - ―
52-Week Range$12.89 - $28.00
Previous CloseN/A
Volume58.94K
Average Volume (3M)350.60K
Market Cap
$5.23B
Enterprise Value$4.14K
Total Cash (Recent Filing)$112.73M
Total Debt (Recent Filing)$448.52M
Price to Earnings (P/E)32.8
Beta0.86
Next Earnings
Aug 11, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume282,294
30 Day Avg. Volume350,598
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.00Price Target Upside41.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.6
Revenue Forecast (FY)$1.28B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue Growth And BDS MomentumSustained top-line growth, driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, indicates durable end-market demand for injectable packaging. Recurring supply relationships and regulatory qualification cycles make this revenue less cyclical and support multi‑year revenue visibility as biologics volumes expand.
Higher Mix Of High-Value Solutions & GLP‑1 ExposureA rising share of high-value products (cartridges, syringes, device assemblies) improves structural margin potential and customer stickiness. Deepening exposure to fast-growing GLP‑1 and biologics markets supports recurring, higher‑value program revenue and long-term demand diversification across premium product lines.
Capacity Expansion And U.S. Manufacturing Build-OutTargeted capex and line conversions are structural enablers to meet growing cartridge/syringe demand and reduce supply constraints. Localizing U.S. production and scaling Latina/Fishers increases customer qualification stickiness, shortens lead times, and supports long-term revenue capture despite near-term ramp costs.
Bears Say
Weak And Volatile Free Cash FlowNegative and inconsistent free cash flow reflects heavy growth capex and uneven cash conversion, limiting financial flexibility. Over the medium term this constrains the company's ability to self-fund expansion, reduce net debt, or return capital unless operating cash conversion improves as new capacity scales.
Engineering Segment Revenue Decline And Backlog RiskA sharp, persistent drop in Engineering revenue reduces diversification and creates execution/timing risk for recovery. Slower customer decision cycles and reliance on new orders mean revenue is sensitive to business development execution and could keep overall growth lumpy until backlog rebuilds.
Margin Pressure From Ramp-Related Depreciation And FX/TariffsCapacity ramp depreciation and persistent FX/tariff headwinds can structurally compress segment margins while volumes ramp. Until new lines reach utilization thresholds, elevated depreciation and external cost pressures may restrain margin scalability and cash conversion despite stronger adjusted EBITDA.
Stevanato Group News
STVN FAQ
What was Stevanato Group Spa’s price range in the past 12 months?
Stevanato Group Spa lowest stock price was $12.89 and its highest was $28.00 in the past 12 months.
What is Stevanato Group Spa’s market cap?
Stevanato Group Spa’s market cap is $5.23B.
When is Stevanato Group Spa’s upcoming earnings report date?
Stevanato Group Spa’s upcoming earnings report date is Aug 11, 2026 which is in 21 days.
How were Stevanato Group Spa’s earnings last quarter?
Stevanato Group Spa released its earnings results on May 07, 2026. The company reported $0.126 earnings per share for the quarter, beating the consensus estimate of $0.118 by $0.008.
Is Stevanato Group Spa overvalued?
According to Wall Street analysts Stevanato Group Spa’s price is currently Undervalued.
Does Stevanato Group Spa pay dividends?
Stevanato Group Spa pays a Annually dividend of $0.062 which represents an annual dividend yield of 0.32%. See more information on Stevanato Group Spa dividends here
What is Stevanato Group Spa’s EPS estimate?
Stevanato Group Spa’s EPS estimate is 0.14.
How many shares outstanding does Stevanato Group Spa have?
Stevanato Group Spa has 49,709,717 shares outstanding.
What happened to Stevanato Group Spa’s price movement after its last earnings report?
Stevanato Group Spa reported an EPS of $0.126 in its last earnings report, beating expectations of $0.118. Following the earnings report the stock price went down -5.108%.
Which hedge fund is a major shareholder of Stevanato Group Spa?
Currently, no hedge funds are holding shares in STVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (41.66% Upside)
$22.00 (41.66% Upside)
Blogger Sentiment
Bullish
STVN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 504.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.52%
12-Months-Change
Fundamentals
Return on Equity
0.32%
Trailing 12-Months
Asset Growth
18.58%
Trailing 12-Months
Company Description
Stevanato Group Spa
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
STVN Stock 12 Month Forecast
Average Price Target
$22.00
▲(41.66% Upside)
Technical Analysis
Ownership Overview
2.77% Insiders
43.39% Mutual Funds
3.07% Other Institutional Investors
48.59% Public Companies and
Individual Investors